Welcome to our dedicated page for Fulcrum Therapeutics news (Ticker: FULC), a resource for investors and traders seeking the latest updates and insights on Fulcrum Therapeutics stock.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) is a clinical-stage biopharmaceutical company that reports frequent updates related to its work in genetically defined rare diseases. Company news regularly highlights progress for its lead program, pociredir, an investigational oral small molecule designed to increase fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD).
Investors and followers of FULC can expect news items covering clinical trial milestones, such as initial and updated data from the Phase 1b PIONEER trial of pociredir in adults with severe SCD. Fulcrum’s releases describe dose-escalation cohorts, changes in HbF levels, markers of hemolysis and anemia, and observations related to vaso-occlusive crises, along with safety and tolerability findings.
Fulcrum also issues corporate and financial announcements, including quarterly financial results, cash runway commentary, and details of public offerings of common stock and pre-funded warrants. Additional news may feature participation in major medical and investor conferences, such as the American Society of Hematology Annual Meeting and the J.P. Morgan Healthcare Conference, where the company presents clinical and preclinical data.
Other updates include disclosures on early-stage programs, such as calmodulin pathway modulators for bone marrow failure syndromes and preclinical data for EED inhibitor candidates in oncology models, as well as routine items like inducement stock option grants under Nasdaq Listing Rule 5635(c)(4). For readers tracking FULC, this news stream provides insight into the evolution of Fulcrum’s pipeline, its clinical development strategy in sickle cell disease, and its broader efforts in gene-expression modulation for rare diseases.
Fulcrum Therapeutics (NASDAQ: FULC) provided a business update and reported Q3 2021 results, highlighting progress in clinical trials. The company is set to initiate a Phase 1b trial for FTX-6058 in sickle cell disease by year-end 2021, with an investigational new drug application expected for other hemoglobinopathies shortly after. Fulcrum raised $144.2 million in August 2021, securing its cash runway into 2024. Collaboration revenue rose to $4.9 million from $1.8 million YoY, while net loss increased to $20.7 million versus $19.0 million YoY. Key updates on losmapimod are anticipated in Q1 2022.
Fulcrum Therapeutics (Nasdaq: FULC) announced management participation in key investor conferences. These include the Credit Suisse 30th Annual Virtual Healthcare Conference on November 11, 2021 at 4:20pm ET, the Stifel Virtual Healthcare Conference on November 17, 2021 at 11:20am ET, and the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 30, 2021. Live audio webcasts will be accessible via the Investor Relations section of the Fulcrum website, with archived replays available for 30 days.
Fulcrum Therapeutics (FULC) will release its Q3 2021 financial results on November 4, 2021, before U.S. markets open. A conference call and webcast will follow at 8:00 a.m. ET to discuss results and recent corporate developments. Fulcrum's focus is on patients with genetically defined rare diseases, with notable advancements including losmapimod in Phase 2 trials for facioscapulohumeral muscular dystrophy and FTX-6058 in Phase 1 trials for sickle cell disease and beta-thalassemia.
Fulcrum Therapeutics (Nasdaq: FULC) announced the approval of an inducement award for Naomi Aoki, the newly appointed SVP of Communications and Investor Relations, on September 10, 2021. The grant includes a nonstatutory stock option for 58,000 shares at an exercise price of $28.21, the closing price on September 30, 2021. The option has a ten-year term and vests over four years, promoting retention through gradual vesting. Fulcrum Therapeutics focuses on developing treatments for genetically defined rare diseases, advancing losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease.
Fulcrum Therapeutics (FULC) has announced the presentation of multiple posters and oral presentations on losmapimod for facioscapulohumeral muscular dystrophy (FSHD) at the Virtual Congress of the World Muscle Society. Results from the Phase 2b ReDUX4 trial indicate significant benefits across various clinical endpoints. The company plans to meet with regulators in Q4 2021 and provide updates on losmapimod's clinical path in Q1 2022. FSHD currently has no approved therapies, highlighting the importance of this research.
Fulcrum Therapeutics (Nasdaq: FULC) announced the grant of a nonstatutory stock option to Mel Hayes, its newly appointed Chief Commercial Officer, as part of an inducement award. The award includes an option to purchase up to 140,000 shares at an exercise price of $28.49. This grant, approved on August 4, 2021, is valid for ten years and vests over four years. Fulcrum focuses on patients with rare genetically defined diseases, advancing treatments like losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease.
Fulcrum Therapeutics (Nasdaq: FULC) has appointed Mel Hayes as Chief Commercial Officer, effective September 7, 2021. Hayes, an industry veteran with over 25 years of experience in product commercialization, will lead the company's global strategy to maximize the potential of its therapies. The company is transitioning to a commercial-stage organization following advancements in its product pipeline, including losmapimod and FTX-6058, aimed at treating rare genetic diseases.
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company focused on genetically defined rare diseases, announced its participation in key investor conferences. Management will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 4:15 p.m. ET, followed by the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET, and the Cantor Virtual Global Healthcare Conference on September 28, 2021, at 3:20 p.m. ET. Live audio webcasts will be accessible on Fulcrum's Investor Relations page.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) announced the closing of its public offering of 7,590,000 shares at $19.00 each, raising $144.2 million in gross proceeds. The offering included 990,000 shares purchased at the underwriters' exercise option. The shares were sold under a previously effective SEC registration statement. SVB Leerink, Piper Sandler & Co., and Stifel served as joint bookrunning managers, while H.C. Wainwright & Co. led the offering management. The funds will support Fulcrum's ongoing clinical development of therapeutics for genetically defined rare diseases.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) has announced the pricing of a public offering of 6,600,000 shares of its common stock at $19.00 per share, aiming for total gross proceeds of approximately $125 million before expenses. The offering is expected to close on August 16, 2021. Additionally, underwriters have a 30-day option to purchase up to 990,000 extra shares. The offering is being conducted under a shelf registration statement and involves joint bookrunning managers SVB Leerink, Piper Sandler & Co., and Stifel.
FAQ
What is the current stock price of Fulcrum Therapeutics (FULC)?
What is the market cap of Fulcrum Therapeutics (FULC)?
